Markus Hansson
Overview
Explore the profile of Markus Hansson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nilsson M, Martner A, Wennstrom L, Hansson M, Thoren F, Hellstrand K
Leuk Lymphoma
. 2024 Dec;
:1-3.
PMID: 39719012
No abstract available.
2.
Went M, Duran-Lozano L, Halldorsson G, Gunnell A, Ugidos-Damboriena N, Law P, et al.
Nat Commun
. 2024 Aug;
15(1):6644.
PMID: 39103364
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling...
3.
Einarsdottir S, Sverrisdottir I, Villegas-Scivetti M, Day C, Turesson I, Juliusson G, et al.
Haematologica
. 2024 Jun;
110(1):179-182.
PMID: 38934063
No abstract available.
4.
Veskovski L, Jakobsson I, Andersson P, Gustafsson T, Sedigh A, Knut-Bojanowska D, et al.
EJHaem
. 2024 Jun;
5(3):455-461.
PMID: 38895087
Multiple myeloma (MM) is a disease, that at times poses diagnostic and monitoring challenges. Over the last decades laboratory methods have been expanded with serum free light chain (FLC) analysis....
5.
Uttervall K, Tatting L, Lemonakis K, Majd M, Crafoord J, Olsson M, et al.
Cancer Med
. 2024 Apr;
13(8):e7048.
PMID: 38651177
Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug...
6.
Askman S, Westerlund J, Pettersson A, Hellmark T, Johansson A, Wichert S, et al.
Eur J Haematol
. 2024 Mar;
113(1):72-81.
PMID: 38553844
Objectives: Bacterial infections are common and a major cause of morbidity and mortality in multiple myeloma (MM). We have investigated the function of polymorphonuclear leukocyte (PMN), the immune system's first...
7.
Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Saily M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473382
Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of...
8.
Hemminki K, Zitricky F, Forsti A, Silvennoinen R, Vangsted A, Hansson M
Blood Cancer J
. 2024 Mar;
14(1):43.
PMID: 38467614
No abstract available.
9.
Abildgaard N, Anttila P, Waage A, Rubin K, Orstavik S, Bent-Ennakhil N, et al.
Eur J Cancer
. 2024 Feb;
201:113921.
PMID: 38377776
Aim: The Health outcomes and Understanding of MyelomA multi-National Study (HUMANS) was a large-scale, retrospective study conducted across Denmark, Finland and Sweden using linked data from national registries. We describe...
10.
Nielsen L, Schjesvold F, Moller S, Guldbrandsen N, Hansson M, Remes K, et al.
J Patient Rep Outcomes
. 2024 Feb;
8(1):15.
PMID: 38315268
Background: Decisions regarding maintenance therapy in patients with multiple myeloma should be based on both treatment efficacy and health-related quality of life (HRQL) consequences. In the CARFI trial, patients with...